Inhibitor Therapeutics, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $2.6M | $2.2M | $2.6M | $1.7M | $2.4M | $1.1M | — |
| SG&A Expense | $1.9M | $2.9M | $4.4M | $2.3M | $1.5M | $817.3K | $560.7K |
| Operating Income | $-4.6M | $-5.1M | $-7.0M | $-3.9M | $-3.9M | $-2.0M | $-560.7K |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | $37.5K | $1.9K | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net Income | $-4.6M | $-5.1M | $-7.0M | $-3.9M | $-4.0M | $-1.8M | $186.4K |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.04 | $-0.10 | $0.01 |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.04 | $-0.10 | $0.01 |
| Shares Outstanding (Basic) | 370.1M | 369.6M | 353.4M | 245.4M | 211.4M | 17.9M | 13.6M |
| Shares Outstanding (Diluted) | 370.1M | 369.6M | 353.4M | 245.4M | 211.4M | 17.9M | 13.6M |
| Dividends Per Share | — | — | — | — | — | — | — |